Lubman Ellen has filed 3 insider transactions across 1 company since January 2023.
Most recent transaction: a grant/award of 131900 shares of Werewolf Therapeutics, Inc. ($HOWL) on January 02, 2025.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 2, 2025 | Werewolf Therapeutics, Inc. | $HOWL | Lubman Ellen | Chief Business Officer | A | Stock Option (right to buy) | 131900 | $0.00 | 131,900.0000 | 0 | 9999.99% | 0.00% |
| Jan. 2, 2024 | Werewolf Therapeutics, Inc. | $HOWL | Lubman Ellen | Chief Business Officer | A | Stock Option (right to buy) | 131900 | $0.00 | 131,900.0000 | 0 | 9999.99% | 0.00% |
| Jan. 3, 2023 | Werewolf Therapeutics, Inc. | $HOWL | Lubman Ellen | Chief Business Officer | A | Stock Option (right to buy) | 86200 | $0.00 | 86,200.0000 | 0 | 9999.99% | 0.00% |